Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts
Jing Zhang, … , Daniel C. Flynn, Gary E. Gallick
Jing Zhang, … , Daniel C. Flynn, Gary E. Gallick
Published October 1, 2007
Citation Information: J Clin Invest. 2007;117(10):2962-2973. https://doi.org/10.1172/JCI30710.
View: Text | PDF
Research Article Oncology

AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts

  • Text
  • PDF
Abstract

The actin filament–associated protein AFAP-110 is an actin cross-linking protein first identified as a substrate of the viral oncogene v-Src. AFAP-110 regulates actin cytoskeleton integrity but also functions as an adaptor protein that affects crosstalk between Src and PKC. Here we investigated the roles of AFAP-110 in the tumorigenic process of prostate carcinoma. Using immunohistochemistry of human tissue arrays, we found that AFAP-110 was absent or expressed at very low levels in normal prostatic epithelium and benign prostatic hyperplasia but significantly increased in prostate carcinomas. The level of AFAP-110 in carcinomas correlated with the Gleason scores. Downregulation of AFAP-110 in PC3 prostate cancer cells inhibited cell proliferation in vitro and tumorigenicity and growth in orthotopic nude mouse models. Furthermore, downmodulation of AFAP-110 resulted in decreased cell-matrix adhesion and cell migration, defective focal adhesions, and reduced integrin β1 expression. Reintroduction of avian AFAP-110 or a mutant disabling its interaction with Src restored these properties. However, expression of an AFAP-110 lacking the PKC-interacting domain failed to restore properties of parental cells. Thus, increased expression of AFAP-110 is associated with progressive stages of prostate cancer and is critical for tumorigenic growth, in part by regulating focal contacts in a PKC-dependent mechanism.

Authors

Jing Zhang, Serk In Park, Marlene C. Artime, Justin M. Summy, Ami N. Shah, Joshua A. Bomser, Andrea Dorfleutner, Daniel C. Flynn, Gary E. Gallick

×

Figure 1

Expression of AFAP-110 in normal and pathologic prostate tissues.

Options: View larger image (or click on image) Download as PowerPoint
Expression of AFAP-110 in normal and pathologic prostate tissues.
Human ...
Human prostate tissue arrays were subjected to immunohistochemical analyses with a monoclonal mouse anti–AFAP-110 primary antibody and a biotinylated goat anti-mouse secondary antibody after antigen retrieval. Brown indicates positive staining. Representative images from tissues with different pathologic characteristics are shown. GS, Gleason score. Scale bars: 100 μm. (A) Prostatic smooth muscles. Note that AFAP-110 is expressed in the cytoplasm of smooth muscle cells. (B) Normal prostate epithelium. Green arrow indicates luminal secretory cells, and red arrow indicates basal layer cells. (C) BPH. Note that immunoreactivity for AFAP-110 is not present in the secretory epithelial cells (green arrows). The proliferating basal cells (red arrows) demonstrate weak to moderate staining. (D) Prostatic adenocarcinoma with a Gleason score less than 7. (E) Prostate adenocarcinoma with a Gleason score greater than or equal to 7. Note that tumor foci demonstrate strong labeling for AFAP-110, while connective tissues in the stroma of prostate cancer specimen are not stained for AFAP-110.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts